

Antigens and Antibodies for Immunodiagnosics



Distributed by:

CliniSciences Group

INDEX

1	Infectious Diseases.....	1
2	Veterinary	2
3	Inflammation	3
4	Hormone.....	6
5	Apolipoprotein.....	7
6	Cardiac.....	7
7	Tumor.....	10
8	Metabolic Syndrome	13
9	Kidney Diseases	14
10	Hepatobiliary Diseases	14
11	Neuroscience.....	15
12	Autoimmune.....	15
13	Allergen	16
14	SARS-CoV-2.....	17
15	Immunodiagnosics Reagent Solutions.....	37
16	Support.....	40

Distributed by:

CliniSciences Group



Dedicated & Professional

Novoprotein Scientific Inc. (Novoprotein) is a high-tech enterprise with more than 10 years of extensive experience in the recombinant protein industry, focusing on protein technology, and advanced in R&D, production, sales, and application solutions to raw materials and techniques for biopharmaceuticals, in vitro diagnosis, mRNA vaccines, and basic life science research. Our principal products include target proteins and cytokines, recombinant antibodies, molecular enzymes and reagents, as well as providing related technical services. Novoprotein possesses R&D and manufacturing bases in Shanghai, Suzhou, and Heze.

novoprotein
近岸蛋白

Distributed by:

CliniSciences Group

1 Infectious Diseases

Antigen

Product Name	Source	Cat. No.
HIV p24	<i>E. coli</i>	DRA19
Influenza A H1N1 (A/Hong Kong/1/1968) NP	<i>E. coli</i>	DRA158
Influenza A H1N1 (A/New Caledonia/20/1999) NP	Human Cells	DRA148
Influenza A H1N1 (A/Taiwan/01/1986) HA	Human Cells	DRA127
Influenza A H5N1 (A/Hong Kong/483/1997) HA	Human Cells	DRA132
Influenza A H7N7 (A/Netherlands/219/2003) HA	Human Cells	DRA141
Influenza A H9N2 (A/chicken/China/GD2021/2021) HA	Human Cells	DRA201
Influenza A H3N2 (A/Hong Kong/1/1968)NP	Human Cells	DRA130
Influenza B (B/Singapore/222/1979) HA	Human Cells	DRA142
Influenza B (B/Beijing/184/93) NP	Human Cells	DRA131
Influenza B (B/Yamagata/16/1988) HA	Human Cells	DRA163
Influenza B (B/Victoria/504/2000) HA	Human Cells	DRA147
MPXV A29L	<i>E. coli</i>	DRA207
MPXV A29L	Human Cells	DRA208
MPXV A29L (110AA)	Human Cells	DRA206
MPXV A30L	Human Cells	DRA219
MPXV A35R	Human Cells	DRA209
MPXV M1R	Human Cells	DRA210
MPXV B6R	Human Cells	DRA211
MPXV E8L	Human Cells	DRA212
NDV HN	Human Cells	DRA243
RSV G	Human Cells	DRA231
RSV F-trimer	Human Cells	DRA230
TB CFP-10	<i>E. coli</i>	DRA28
TB P38	<i>E. coli</i>	DRA27
TmpA	<i>E. coli</i>	DRA174
TP0453	<i>E. coli</i>	DRA179
TP15	<i>E. coli</i>	DRA172
TP17	<i>E. coli</i>	DRA94
TP47	<i>E. coli</i>	DRA151
VZV Envelope Glycoprotein E	Human Cells	DRA224

Distributed by:

CliniSciences Group

Antibody

Product Name	Source	Cat. No.
FluA HA antibody (8F10)	Human Cells	DA077
FluA NA Antibody (9E4)	Human Cells	DA076
FluA NP Antibody (3C8)	Human Cells	DA074
FluA NP Antibody (4F8)	Human Cells	DA086
FluA NP Antibody (5G11)	Human Cells	DA087
FluB NP Antibody (3C11)	Human Cells	DA089
FluB NP Antibody (7F9)	Human Cells	DA075
FluB NP Antibody (8B9)	Human Cells	DA088
MPXV A35R Antibody	Human Cells	NC083
MPXV B6R Antibody	Human Cells	NC082
RSV F Antibody (11A9)	Human Cells	DA091
RSV G Antibody (2G7)	Human Cells	DA092

2 Veterinary

Antigen

Product Name	Source	Cat. No.
ASFV p30	<i>E. coli</i>	DRA250
ASFV p72 complex	Human Cells	DRA162
ASFV pS273R	<i>E. coli</i>	DRA160
BoHV-1 gE	Human Cells	DRA167
BoHV-1 gD	Human Cells	DRA186
BPIV-3 Nucleocapsid Protein	<i>E. coli</i>	DRA171
BVDV-2 E2	Human Cells	DRA225
CSFV E2	Human Cells	DRA227
NDV HN	Human Cells	DRA243
PEDV Nucleocapsid Protein	<i>E. coli</i>	DRA173
PEDV S1	Human Cells	DRA164
PRRSV nsp7	<i>E. coli</i>	DRA222
PRV gB Protein	Human Cells	DRA245
TGEV S1	Human Cells	DRA181

Distributed by:

CliniSciences Group

3 Inflammation

Antigen

Product Name	Source	Cat. No.
AIAT	Human Cells	C533
Calprotectin	<i>E. coli</i>	DC796
CRP	Human Cells	DRA180
Haptoglobin	Human Cells	DCD97
HBP	Human Cells	DC430
IFN γ	<i>E. coli</i>	DC014
IL-10	Human Cells	DCD04
IL-6	<i>E. coli</i>	C009
IL-8	<i>E. coli</i>	DC037
LOX-1	Human Cells	C524
MMP-3	Human Cells	DC378
Oncostatin M	<i>E. coli</i>	C099
PCT	Human Cells	DCA21
S100-A8	<i>E. coli</i>	DC794
S100-A9	<i>E. coli</i>	DC795
S100-P	<i>E. coli</i>	C258
SAA-1	<i>E. coli</i>	DC633
TNF α	<i>E. coli</i>	DC008

Antibody


Product Name	Source	Cat. No.
IL-6 antibody (12H6)	Human Cells	DA011
IL-6 antibody (15H5)	Human Cells	DA012
IL-6 antibody (19D6)	Human Cells	DA013
MMP-3 Antibody (6A11)	Human Cells	DA062
MMP-3 Antibody (9B5)	Human Cells	DA063

Distributed by:


CliniSciences Group

Validation Data


• IL-6 Antibody (Cat. No.: DA011/12/13)






EC50: 47.89ng/ml





EC50: 150 ng/ml



EC50: 50 ng/ml




Stability is confirmed by binding ability with human IL-6 (Cat. No.: C009). The result showed antibody bioactivity has no significant differences after placed at 37 °C for 7 days.




R Square of TRFIA and CLIA Clinical Correlation for MAb pair DA013-DA012 is 0.98

Validation Data



• MMP-3 Antibody (Cat. No.: DA062/63)





Affinity: 0.12 nM (BLI)





Affinity: $<10^{-3}$ nM (BLI)



Stability is tested by binding ability with MMP-3 antigen after storage for 14 days at 4°C . The results showed no significant differences among these samples.



Stability is tested by binding ability with MMP-3 antigen after 14 times freeze-thaw. The results showed no significant differences among these samples.




Stability is tested by binding ability with MMP-3 antigen after storage for 14 days at 25°C . The results showed no significant differences among these samples.

Distributed by:

CliniSciences Group

• MMP-3 Antibody (Cat. No.: DA062/63)



LFIA linear range for MMP3 MAb pair is 1-1000ng/mL

4 Hormone

Antigen

Product Name	Source	Cat. No.
AMHN	Human Cells	DRA15
CGB3	Human Cells	DCC93
FSH	Human Cells	DCM28
FSHB	Human Cells	DCA13
HCGA	Human Cells	DRA09
Lactoferrin	Human Cells	DC900
PRL	Human Cells	DCM10
PTH	<i>E. coli</i>	DC010
SP-10	Human Cells	DC421
SHBG	Human Cells	DRA25
TPO	Human Cells	DRA22
TSH	Human Cells	DRA17

Distributed by:

CliniSciences Group

5 Apolipoprotein

Antigen

Product Name	Source	Cat. No.
apo A-I	Human Cells	DC511
apo A-II	Human Cells	DCC76
apo A-IV	Human Cells	CA08
apo C-II	<i>E. coli</i>	DCB66
apo D	Human Cells	C556
apo E	Human Cells	DCI02
apo H	Human Cells	DC432
apo M	Human Cells	C557

6 Cardiac

Antigen

Product Name	Source	Cat. No.
CKBB	<i>E. coli</i>	DRA02
CKMB type I	<i>E. coli</i>	DRA12
CKMM	Human Cells	DCC96
cTnC	<i>E. coli</i>	DRA10
cTnI	<i>E. coli</i>	DRA04
cTnT	<i>E. coli</i>	DRA16
FABP3	<i>E. coli</i>	DC135
FABP4	<i>E. coli</i>	C136
Galectin-3	<i>E. coli</i>	DC068
GDF-15	Human Cells	DRA24
GDF-15	<i>E. coli</i>	DRA26
Lp-PLA2	Human Cells	DC624
Myo	<i>E. coli</i>	DRA06
NT-proANP	<i>E. coli</i>	DRA11
NT-proBNP	<i>E. coli</i>	DCM29
PAI-1/Serpin E1	Human Cells	DC537
proBNP	<i>E. coli</i>	DC154
sCD40L	Human Cells	DCI56
sST2	Human Cells	DCI84

Distributed by:


CliniSciences Group

Antibody

Product Name	Source	Cat. No.
GDF-15 antibody(11B2)	Human Cells	DA016
GDF-15 antibody(15E1)	Human Cells	DA015
GDF-15 antibody(9F3)	Human Cells	DA017
Lp-PLA2 Antibody (3B7)	Human Cells	DA058
Lp-PLA2 Antibody (4E11)	Human Cells	DA056
Lp-PLA2 Antibody (6H3)	Human Cells	DA059
Lp-PLA2 Antibody (7G5)	Human Cells	DA057
sCD40L antibody (5A4)	Human Cells	DA060
sCD40L antibody(11F2)	Human Cells	DA061
sST2 Antibody	Human Cells	DA014

Validation Data


• Lp-PLA2 Antibody (Cat. No.: DA056/57/58/59)



Affinity: $<10^{-3}$ nM(BLI)

Coated Antibody	Detecting Antibody			
	DA056(4E11)	DA057(7G5)	DA058(3B7)	DA059(6H3)
DA056(4E11)	—	+++	++	++
DA057(7G5)	++	—	++	++
DA058(3B7)	+	++	—	+
DA059(6H3)	++	++	+	—

Lp-pLA2 Antibody Pairing




LFIA linear range for Lp-pLA2 Mab pair is 1-1000ng/mL

Distributed by:


CliniSciences Group

Validation Data


- GDF-15 Antibody (Cat. No.: DA015/16/17)






EC50: 77.2 ng/ml



EC50: 190.9 ng/ml



EC50: 78.9 ng/ml



Stability is confirmed by binding ability with human GDF-15 (Cat. No.: DRA26). The result showed antibody bioactivity has no significant differences after placed at 37 °C for 7 days.

Distributed by:

CliniSciences Group

7 Tumor

Antigen

Product Name	Source	Cat. No.
AFP	Human Cells	DCS71
Alpha-2-HS-glycoprotein	Human Cells	C425
Annexin A1	<i>E. coli</i>	C093
BDNF	<i>E. coli</i>	DC076
CA 15-3	Human Cells	DCS58
Cathepsin B	Human Cells	C398
CCL2/MCP-1	<i>E. coli</i>	DCM78
CEA	Human Cells	DCM95
CXCL10	<i>E. coli</i>	DC054
CYFRA21-1	<i>E. coli</i>	DRA08
EGF	<i>E. coli</i>	C029
Estrogen Receptor α	<i>E. coli</i>	DCE11
FABP5	<i>E. coli</i>	C137
FABP6	<i>E. coli</i>	C221
FABP7	<i>E. coli</i>	C138
FABP8	<i>E. coli</i>	C238
FGF-1	<i>E. coli</i>	C049
FGF-2	<i>E. coli</i>	DC046
FLT-3 ligand	Human Cells	CA82
G-CSF	<i>E. coli</i>	C002
GM-CSF	<i>P. pastoris</i>	DC040
GOLM1	Human Cells	DC933
HE4	Human Cells	DC550
HER2	Human Cells	DCP69
IGF-I	<i>E. coli</i>	DC031
IGFBP-1	Human Cells	DCU66
IGFBP-3	Human Cells	DRA23
IGFBP-4	Human Cells	C347
IGFBP-5	Human Cells	DCA41
Kallikrein-10	Human Cells	C360
KGF	<i>E. coli</i>	CH73
Kininogen-1	Human Cells	DC523
KLKB1	Human Cells	CJ20
LDHA	<i>E. coli</i>	DC235

Distributed by:

CliniSciences Group

Product Name	Source	Cat. No.
LDHB	<i>E. coli</i>	DC236
MUC-1	Human Cells	DRA187
NGFβ	<i>E. coli</i>	C060
OPG	Human Cells	C325
Osteopontin	Human Cells	DC544
PAP	Human Cells	DC420
PG I	<i>E. coli</i>	DRA07
PG II	Human Cells	DRA29
SCF	Human Cells	DCD53
SDF-1α	<i>E. coli</i>	C121
TNF-β	<i>E. coli</i>	DC181
TRAIL	<i>E. coli</i>	DC022
u-PA	Human Cells	C393
VEGF165	Human Cells	DC083
Vitronectin	Human Cells	DC395

Antibody


Product Name	Source	Cat. No.
VEGF-165 Antibody (10F9)	Human Cells	DA021
VEGF-165 Antibody (12E3)	Human Cells	DA019
VEGF-165 Antibody (3A6)	Human Cells	DA067
VEGF-165 Antibody (5E7)	Human Cells	DA082
VEGF-165 Antibody (6D9)	Human Cells	DA083

Distributed by:


CliniSciences Group

Validation Data


- VEGF-165 Antibody (Cat. No.: DA019/21)




EC50: 110 ng/ml





EC50: 49.5 ng/ml



Affinity: $<10^{-3}$ nM (BLI)



Affinity: 0.004 nM (BLI)



Stability is confirmed by binding ability with human VEGF-165 (Cat. No.: DC083). The result showed antibody bioactivity has no significant differences after placed at 37 °C for 7 days.

8 Metabolic Syndrome

Antigen


Product Name	Source	Cat. No.
Adiponectin	Human Cells	DC552
CFD	Human Cells	CP27
FABP2	<i>E. coli</i>	DC134
Leptin	<i>E. coli</i>	DC067
Platelet Factor IV	Human Cells	CJ27
sTR	Human Cells	DCU75
Thrombospondin-1	Human Cells	C646

Antibody


Product Name	Source	Cat. No.
Adiponectin antibody(10A10)	Human Cells	DA024
Adiponectin antibody(13E9)	Human Cells	DA023
Adiponectin antibody(6F1)	Human Cells	DA022

Validation Data



• Adiponectin Antibody (Cat. No.: DA022/24)



EC50: 8.47 ng/ml



EC50: 13.37 ng/ml




Stability is confirmed by binding ability with human Adiponectin (Cat. No.: DC552). The result showed antibody bioactivity has no significant differences after placed at 37 °C for 7 days

Distributed by:

CliniSciences Group

• Pair Recommendations



Adiponectin Antibody Pairing

9 Kidney Diseases

Antigen

Product Name	Source	Cat. No.
Albumin	<i>P.Pichia</i>	DCP01
B2M	<i>E. coli</i>	CH02
Cys C	Human Cells	DCI55
KIM-1	Human Cells	DRA03
NGAL	<i>E. coli</i>	DCH31
RBP4	<i>E. coli</i>	DC169

10 Hepatobiliary Diseases

Antigen

Product Name	Source	Cat. No.
5'-Nucleotidase	Human Cells	C446
α1-ACT	Human Cells	C534
AGP2	Human Cells	DCD54
FABP1	<i>E. coli</i>	C133
Fibronectin fragment	<i>E. coli</i>	CH38
MMP-1	Human Cells	DC374
TIMP-1	Human Cells	C456
Transthyretin	Human Cells	C545

Distributed by:

CliniSciences Group

11 Neuroscience

Antigen

Product Name	Source	Cat. No.
Amyloid β A4	Human Cells	DRA20
NNE	<i>E. coli</i>	DRA05
NSE	<i>E. coli</i>	DRA01
NT3	<i>E. coli</i>	DC079
S100-B	<i>E. coli</i>	DCM19

12 Autoimmune

Antigen

Product Name	Source	Cat. No.
GARS	<i>E. coli</i>	DE055
Jo-1	<i>E. coli</i>	DE045
MPO	Human Cells	DCS73
Proteinase 3	Human Cells	DC628
SLA	<i>E. coli</i>	DE054
Sm RNP-P2	Human Cells	DRA118
SS-A/Ro 52KD	<i>E. coli</i>	DRA204
SS-B	<i>E. coli</i>	DRA70
tTG	<i>E. coli</i>	DE056
U1 snRNP-A	<i>E. coli</i>	DRA203

Distributed by:

CliniSciences Group

13 Allergen

Antigen

Product Name	Source	Cat. No.
American House Dust Mite Der f 2	Human Cells	DRA102
Bovine Bos d 11	<i>E. coli</i>	DRA105
Bovine Bos d 4	Human Cells	DRA103
Bovine Bos d 5	Human Cells	DRA124
Bovine Bos d 8	Human Cells	DRA108
Bovine Bos d 8 (E. coli)	<i>E. coli</i>	DRA119
Charybdis feriata Cha f 1	<i>E. coli</i>	DRA97
Chicken Gal d 1	Human Cells	DRA115
Chicken Gal d 2	<i>E. coli</i>	DRA109
Chicken Gal d 3	Human Cells	DRA123
Chicken Gal d 4	Human Cells	DRA104
Chicken Gal d 5	Human Cells	DRA114
Chicken Gal d 6	Human Cells	DRA116
Dermatophagoides pteronyssinus Der p 2	Human Cells	DRA117
European House Dust Mite Der p10	<i>E. coli</i>	DRA99
Penaeus aztecus Pen a 1	<i>E. coli</i>	DRA98

14 SARS-CoV-2

Antibody

Product Name	Source	Cat. No.
SARS-CoV-2 NP Antibody (6G9)	Human Cells	DA027
SARS-CoV-2 NP Antibody (9C2)	Human Cells	DA044
SARS-CoV-2 S Antibody (5E8)	Human Cells	DA041
SARS-CoV-2 S Antibody (IgG&IgM Positive Control)	Human Cells	DA032
SARS-CoV-2 NP Antibody (IgG&IgM Positive Control)	Human Cells	DA033
SARS-CoV-2 S-hIgG1 Neutralizing Antibody (8A5)	Human Cells	DA034
SARS-CoV-2 S-mIgG1 Neutralizing Antibody (8A5)	Human Cells	DA035
SARS-CoV-2 S-cIgG1 Neutralizing Antibody (8A5)	Human Cells	DA036
SARS-CoV-2 S-hIgM Neutralizing Antibody (8A5)	Human Cells	DA039
SARS-CoV-2 S-hIgA Neutralizing Antibody (8A5)	Human Cells	DA040

Antigen Omicron Protein

Product Name	Source	Cat. No.
SARS-CoV-2 S-trimer Protein (CH.1.1, C-6His)	Human Cells	DRA242
SARS-CoV-2 S-trimer Protein (XBB.1.5, C-6His)	Human Cells	DRA237
SARS-CoV-2 S-trimer Protein (XBB, C-6His)	Human Cells	DRA238
SARS-CoV-2 S-trimer Protein (BQ.1.1, C-6His)	Human Cells	DRA235
SARS-CoV-2 S-trimer Protein (BA.5, C-6His)	Human Cells	DRA236
SARS-CoV-2 S-trimer Protein (BF.7, C-6His)	Human Cells	DRA229
SARS-CoV-2 S-trimer Protein (BA.4, C-6His)	Human Cells	DRA213
SARS-CoV-2 S-trimer Protein (BA.2.75, C-6His)	Human Cells	DRA218
SARS-CoV-2 S-trimer Protein (BA.2.12.1, C-6His)	Human Cells	DRA220
SARS-CoV-2 S-trimer Protein (BA.2, C-6His)	Human Cells	DRA200
SARS-CoV-2 S-trimer Protein (Deltacron, C-6His)	Human Cells	DRA202
SARS-CoV-2 S-trimer Protein (B.1.1.529, C-6His)	Human Cells	DRA193
SARS-CoV-2 S-trimer Protein (B.1.1.529, C-6His)V2	Human Cells	DRA194
SARS-CoV-2 S Protein RBD (CH.1.1, C-6His)	Human Cells	DRA241
SARS-CoV-2 S Protein RBD (XBB.1.5, C-6His)	Human Cells	DRA234
SARS-CoV-2 S Protein RBD (XBB, C-6His)	Human Cells	DRA233
SARS-CoV-2 S Protein RBD (BQ.1.1, C-6His)	Human Cells	DRA232
SARS-CoV-2 S Protein RBD (BF.7, C-6His)	Human Cells	DRA228
SARS-CoV-2 S Protein RBD (BA.4&BA.5, C-6His)	Human Cells	DRA205
SARS-CoV-2 S Protein RBD (BA.3, C-6His)	Human Cells	DRA216
SARS-CoV-2 S Protein RBD (BA.2.75, C-6His)	Human Cells	DRA217

Distributed by:

CliniSciences Group

14 SARS-CoV-2

Product Name	Source	Cat. No.
SARS-CoV-2 S Protein RBD (BA.2.12.1, C-6His)	Human Cells	DRA214
SARS-CoV-2 S Protein RBD (BA.2, C-mFc)	Human Cells	DRA199
SARS-CoV-2 S Protein RBD (BA.2, C-6His)	Human Cells	DRA198
SARS-CoV-2 S Protein RBD (BA.1.1, C-6His)	Human Cells	DRA215
SARS-CoV-2 S Protein RBD (B.1.1.529, C-6His-Avi)	Human Cells	DRA195
SARS-CoV-2 S Protein RBD (B.1.1.529, C-6His)	Human Cells	DRA190
SARS-CoV-2 S1 Protein (B.1.1.529, C-10His)	Human Cells	DRA196
SARS-CoV-2 Nucleocapsid Protein (B.1.1.529, N-6His)	Human Cells	DRA197

Antigen Variants Protein

Product Name	Source	Cat. No.
SARS-CoV-2 S-trimer Protein (Alpha 501Y.V1, C-6His)	Human Cells	DRA136
SARS-CoV-2 S-trimer Protein (Beta N501Y.V2, C-6His)	Human Cells	DRA153
SARS-CoV-2 S-trimer Protein (Gamma P.1, C-6His)	Human Cells	DRA157
SARS-CoV-2 S-trimer Protein (Delta B.1.617.2, C-6His)	Human Cells	DRA168
SARS-CoV-2 S-trimer Protein (Lambda C.37, C-6His)	Human Cells	DRA177
SARS-CoV-2 S-trimer Protein (Eta B.1.525, C-6His)	Human Cells	DRA154
SARS-CoV-2 S-trimer Protein (Mu B.1.621, C-6His)	Human Cells	DRA189
SARS-CoV-2 S-trimer Protein (B.1.620, C-6His)	Human Cells	DRA175
SARS-CoV-2 S-trimer Protein (C.1.2, C-6His)	Human Cells	DRA188
SARS-CoV-2 S Protein RBD (Alpha N501Y, C-mFc)	Human Cells	DRA128
SARS-CoV-2 S Protein RBD (Alpha N501Y, C-6His)	Human Cells	DRA120
SARS-CoV-2 S Protein RBD (Alpha N501Y, C-Fc)	Human Cells	DRA121
SARS-CoV-2 S Protein RBD (Alpha N501Y, C-6His-Avi)	Human Cells	DRA145
SARS-CoV-2 S Protein RBD (Beta 501Y.V2, C-6His)	Human Cells	DRA125
SARS-CoV-2 S Protein RBD (Beta 501Y.V2,C-mFc)	Human Cells	DRA135
SARS-CoV-2 S Protein RBD (Beta 501Y.V2,C-Fc)	Human Cells	DRA126
SARS-CoV-2 S Protein RBD (Gamma P.1, C-mFc)	Human Cells	DRA143
SARS-CoV-2 S Protein RBD (Gamma P.1, C-6His)	Human Cells	DRA144
SARS-CoV-2 S Protein RBD (Delta B.1.617.2, C-6His)	Human Cells	DRA166
SARS-CoV-2 S Protein RBD (Delta B.1.617.2, C-mFc)	Human Cells	DRA178
SARS-CoV-2 S Protein RBD (Lambda C.37, C-6His)	Human Cells	DRA169
SARS-CoV-2 S Protein RBD (Lambda C.37, C-mFc)	Human Cells	DRA170
SARS-CoV-2 S Protein RBD (Kappa B.1.617.1, C-6His)	Human Cells	DRA155
SARS-CoV-2 S Protein RBD (Kappa B.1.617.1, C-mFc)	Human Cells	DRA156
SARS-CoV-2 S Protein RBD (Epsilon CAL.20C, C-mFc)	Human Cells	DRA152

Distributed by:

CliniSciences Group

14 SARS-CoV-2

Product Name	Source	Cat. No.
SARS-CoV-2 S Protein RBD (Epsilon CAL.20C, C-6His)	Human Cells	DRA146
SARS-CoV-2 S Protein RBD (Eta E484K, C-mFc)	Human Cells	DRA129
SARS-CoV-2 S Protein RBD (Eta E484K, C-6His)	Human Cells	DRA134
SARS-CoV-2 S Protein RBD (Mu, B.1.621, C-6His)	Human Cells	DRA185
SARS-CoV-2 S Protein RBD (Mu, B.1.621, C-mFc)	Human Cells	DRA183
SARS-CoV-2 S Protein RBD (C.1.2, C-6His)	Human Cells	DRA182
SARS-CoV-2 S Protein RBD (C.1.2, C-mFc)	Human Cells	DRA184
SARS-CoV-2 S Protein RBD (B.1.620, C-6His)	Human Cells	DRA165
SARS-CoV-2 S Protein RBD (B.1.620, C-mFc)	Human Cells	DRA176
SARS-CoV-2 S1 Protein (Alpha 501Y.V1, C-6His)	Human Cells	DRA133

Antigen Mutant Protein

Product Name	Source	Cat. No.
SARS-CoV-2 S-trimer Protein (D614G, C-6His)	Human Cells	DRA59
SARS-CoV-2 S-trimer Protein (D614G, N439K, C-6His)	Human Cells	DRA100
SARS-CoV-2 S-trimer Protein (D614G, Y453F, C-6His)	Human Cells	DRA112
SARS-CoV-2 ΔFVI-S trimer Protein (C-6His)	Human Cells	DRA113
SARS-CoV-2 S1 Protein (D614G, C-10His)	Human Cells	DRA57
SARS-CoV-2 S Protein RBD (V341I, C-6His)	Human Cells	DRA82
SARS-CoV-2 S Protein RBD (F342L, C-6His)	Human Cells	DRA73
SARS-CoV-2 S Protein RBD (N354D, C-6His)	Human Cells	DRA74
SARS-CoV-2 S Protein RBD (D364Y, C-6His)	Human Cells	DRA81
SARS-CoV-2 S Protein RBD (V367F, C-6His)	Human Cells	DRA76
SARS-CoV-2 S Protein RBD (R408I, C-6His)	Human Cells	DRA75
SARS-CoV-2 S Protein RBD (A435S, C-6His)	Human Cells	DRA77
SARS-CoV-2 S Protein RBD (N439K, C-6His)	Human Cells	DRA101
SARS-CoV-2 S Protein RBD (Y453F, C-6His)	Human Cells	DRA139
SARS-CoV-2 S Protein RBD (K458R, C-6His)	Human Cells	DRA78
SARS-CoV-2 S Protein RBD (G476S, C-6His)	Human Cells	DRA79
SARS-CoV-2 S Protein RBD (V483R, C-6His)	Human Cells	DRA80
SARS-CoV-2 S Protein RBD (E484Q, C-6His)	Human Cells	DRA161
SARS-CoV-2 S Protein RBD (E484Q, C-mFc)	Human Cells	DRA159
SARS-CoV-2 S Protein RBD-SD1 (N354D, D364Y, C-6His)	Human Cells	DRA51
SARS-CoV-2 S Protein RBD-SD1 (V367F, C-6His)	Human Cells	DRA50
SARS-CoV-2 S Protein RBD-SD1 (W436R, C-6His)	Human Cells	DRA52

Distributed by:

CliniSciences Group

14 SARS-CoV-2

Antigen Wild Type Protein

Product Name	Source	Cat. No.
SARS-CoV-2 S-stable trimer Protein(C-6His, low endotoxin)	Human Cells	DRA122
SARS-CoV-2 S-stable trimer Protein (C-6His)	Human Cells	DRA107
SARS-CoV-2 S-trimer Protein (C-6His)	Human Cells	DRA49
SARS-CoV-2 S Protein RBD (C-mFc)	Human Cells	DRA32
SARS-CoV-2 S Protein RBD (C-6His)	Human Cells	DRA36
SARS-CoV-2 S Protein RBD (C-mFc) V2	Human Cells	DRA68
SARS-CoV-2 S Protein RBD (C-6His) V2	Human Cells	DRA72
SARS-CoV-2 S Protein RBD (C-Fc)	Human Cells	NC068
SARS-CoV-2 S Protein RBD-SD1(C-mFc)	Human Cells	DRA38
SARS-CoV-2 S Protein RBD-SD1(C-6His)	Human Cells	DRA42
SARS-CoV-2 S Protein RBD-SD1(C-Avi-6His)	Human Cells	DRA43
SARS-CoV-2 S Protein HR1 (N-6His-Sumo)	<i>E. coli</i>	DRA83
SARS-CoV-2 S Protein HR1	<i>E. coli</i>	DRA84
SARS-CoV-2 S Protein NTD (C-6His)	Human Cells	DRA45
SARS-CoV-2 S Protein NTD (C-6His) V2	Human Cells	DRA85
SARS-CoV-2 S1 Protein (C-mFc)	Human Cells	DRA30
SARS-CoV-2 S1 Protein (non-tag)	Human Cells	DRA35
SARS-CoV-2 S1 Protein (C-Fc)	Human Cells	DRA37
SARS-CoV-2 S1 Protein (C-6His)	Human Cells	DRA47
SARS-CoV-2 S1 Protein (C-10His)	Human Cells	DRA56
SARS-CoV-2 S1 Protein CTD (N-8His-Flag)	Human Cells	DRA46
SARS-CoV-2 S2 Protein (C-Fc)	Human Cells	DRA48
SARS-CoV-2 NP (N-6His)	<i>E. coli</i>	DRA31
SARS-CoV-2 NP (N-6His)V2	<i>E. coli</i>	DRA53
SARS-CoV-2 NP (C-6His)	Human Cells	DRA91
SARS-CoV-2 NP (N-6His-Avi)	<i>E. coli</i>	DRA93
SARS-CoV-2 NP (Truncated)	<i>E. coli</i>	DRA58
SARS-CoV-2 NP NTD (N-6His)	<i>E. coli</i>	DRA40
SARS-CoV-2 NP NTD (N-6His) V2	<i>E. coli</i>	DRA61
SARS-CoV-2 NP CTD (N-6His)	<i>E. coli</i>	DRA41
SARS-CoV-2 NP CTD (N-6His) V2	<i>E. coli</i>	DRA60
SARS-CoV-2 E Protein	<i>E. coli</i>	DRA33

Distributed by:

CliniSciences Group

14 SARS-CoV-2

Antigen Coronavirus Protein

Product Name	Source	Cat. No.
SARS-CoV S-trimer Protein	Human Cells	DRA96
MERS-CoV S-trimer Protein (R751S)	Human Cells	DRA95
HCoV-HKU1 S-trimer Protein	Human Cells	DRA140
HCoV-NL63 Nucleocapsid Protein	<i>E. coli</i>	DRA63
SARS-CoV Nucleocapsid Protein	<i>E. coli</i>	DRA64
MERS-CoV Nucleocapsid Protein	<i>E. coli</i>	DRA65
HCoV-OC43 Nucleocapsid Protein	<i>E. coli</i>	DRA66
HCoV-229E Nucleocapsid Protein	<i>E. coli</i>	DRA67
HCoV-HKU1 Nucleocapsid Protein	<i>E. coli</i>	DRA69

Antigen Receptor Protein

Product Name	Source	Cat. No.
Human ACE-2 (C-Fc)	Human Cells	C05Y
Human ACE-2 (C-Fc) V2	Human Cells	DRA106
Human ACE-2 (C-mFc)	Human Cells	C06A
Human ACE-2 (C-6His)	Human Cells	C419
Human ACE-2 (C-6His) V2	Human Cells	DRA110
Human ACE-2 (C-Avi-6His)	Human Cells	CY51
Human ACE-2 (C-Avi-6His) V2	Human Cells	DRA111
Mouse ACE-2 (C-10His)	Human Cells	C07D
Macaque ACE-2 (C-10His)	Human Cells	C07U
Macaque ACE-2 (C-Fc)	Human Cells	C07W
Human CD147 (C-6His)	Human Cells	C433
Human CD209 (N-Fc)	Human Cells	C07G
Human CD299 (N-8His-Flag)	Human Cells	C07H
Human Cathepsin B (C-6His)	Human Cells	C398
Human Cathepsin L (C-6His)	Human Cells	C401

Distributed by:

CliniSciences Group

14 SARS-CoV-2

Pseudovirion & ACE2 Overexpressed Cells

Product Name	Cat. No.
SARS-CoV-2 Alpha (B.1.1.7, D614G)-GFP-Luc Pseudovirion	XCV04
SARS-CoV-2 Beta (501Y.V2)-GFP-Luc Pseudovirion	XCV05
SARS-CoV-2 Gamma (P.1)-Luc Pseudovirion	XCV06
SARS-CoV-2 Delta (B.1.617.2)-Luc Pseudovirion	XCV08
SARS-CoV-2 Epsilon (B.1.429)-Luc Pseudovirion	XCV07
SARS-CoV-2 Kappa (B.1.617.1)-Luc Pseudovirion	XCV11
SARS-CoV-2 Lambda (C.37)-Luc Pseudovirion	XCV09
SARS-CoV-2 B.1.620-Luc Pseudovirion	XCV10
SARS-CoV-2 (D614G)-Luc Pseudovirion	XCV01
SARS-CoV-2 (D614G)-GFP Pseudovirion	XCV02
SARS-CoV-2 (D614G)-GFP-Luc Pseudovirion	XCV03
293-ACE2 Overexpressed Cells	XCC14


Distributed by:

CliniSciences Group


Validation Data

SARS-CoV-2 Spike Protein Antibody


- Anti-SARS-CoV-2 S-hlgG1 Neutralizing Antibody (8A5) (Cat. No.: DA034)




Affinity: 0.40 nM(BLI)




Affinity: 1.23 nM(BLI)



Anti-SARS-CoV-2 S-mIgG1 Neutralizing Antibody (8A5) can block Human ACE-2-Avi-His (Cat. No.: CY51) and SARS-CoV-2 S-trimer Protein (Cat. No.: DRA49) interaction, the IC50 for this effect is 25ng/ml.



Batch stability is confirmed by binding ability with SARS-CoV-2 S-RBD. The result showed no significant differences among these samples.





Stability is tested by binding ability with SARS-CoV-2 S-RBD after 14 times freeze-thaw . The results showed no significant differences among these samples.

Validation Data


SARS-CoV-2 Spike Protein Antibody

- Anti-SARS-CoV-2 S-IgG1 Neutralizing Antibody (8A5) (Cat. No.: DA034)




Stability is tested by binding ability with SARS-CoV-2 S-RBD after storage for 14 days at 4/25°C. The results showed no significant differences among these samples.

- Anti-SARS-CoV-2 S Antibody (5E8) (Cat. No.: DA041)



EC50: 13.5 ng/ml




EC50: 23.8 ng/ml


Validation Data

SARS-CoV-2 N protein Antibody


- NP Antibody (6G9) (Cat. No.: DA027)



Stability is confirmed by binding ability with SARS-CoV-2 Nucleocapsid Protein (Cat. No.: DRA31). The result showed that product bioactivity is no significant differences among these samples.



Freeze-thaw stability is tested by repeated freeze-thaw cycles. The result showed that product bioactivity is no significant differences after freeze-thawing 10 times.



EC50: 5-30ng/ml

Concentration(pg/ml)	NC	1000	500	100	50	25	Titer(TCID50/ml)	NC	1000	500	250	125	100
Novoprotein	-	+++	++	+	+	+	Novoprotein	-	+++	++	+	+	+



Sensitivity: The lowest recombinant N protein concentration for positive result: 25pg/ml



Sensitivity: The lowest coronavirus culture titer for positive result: 100TCID50/ml

Validation Data

SARS-CoV-2 N protein Antibody

- SARS-CoV-2 NP Antibody (6G9) (Cat. No.: DA027)

Influenza A	Influenza B	Adenovirus	HCoV-OC43	HCoV-229E	HCoV-HKU1
-	-	-	-	-	-







Specificity: None cross reaction (Influenza A, Influenza B, Adenovirus, HCoV-OC43, HCoV-229E, HCoV-HKU1, negative)




Validation Data

Quality Control

- Anti-SARS-CoV-2 Spike mAb (IgG&IgM Positive Control) (Cat. No.: DA032)



- Anti-SARS-CoV-2 NP mAb (IgG&IgM Positive Control) (Cat. No.: DA033)




Distributed by:

CliniSciences Group


Validation Data

SARS-CoV-2 S Protein

- S-trimer Protein (C-6His) (Cat. No.: DRA49)




Purity: Greater than 95%




AP Mol Mass: 550~670kDa, Purity: Greater than 90%

Bind with Recombinant SARS-CoV-2 S-trimer Protein (C-6His)(Cat. No.: DRA49)




EC50: 15-120 ng/ml

Bind with Recombinant SARS-CoV-2 S-trimer Protein (C-6His)(Cat. No.: DRA49)




EC50: 5-30 ng/ml

Bind with Human ACE-2-Fc (Cat. No.: C05Y)



Affinity: 0.125 nM (BLI)

Bind with Anti-SARS-CoV-2 S1 mAb (5D9)(Cat. No.: NC025)





Affinity: 3.88 nM (BLI)



Validation Data

SARS-CoV-2 S Protein



- S-trimer Protein (C-6His) (Cat. No.: DRA49)



Batch stability is confirmed by binding ability with Anti-SARS-CoV-2-S1 mAb(5D9) or ACE-2. The result showed no significant differences among these samples.



Stability is tested by binding ability with Anti-SARS-CoV-2-S1 mAb (5D9) or ACE-2 after 14 times freeze-thaw. The results showed no significant differences among these samples.



Stability is tested by binding ability with ACE-2 after storage for 14 days at 4/25°C. The results showed no significant differences among these samples.



Distributed by:

CliniSciences Group


Validation Data

SARS-CoV-2 S Protein

- S-trimer Protein (C-6His) (Cat. No.: DRA49)






Stability is tested by binding ability with ACE-2 after storage for 14 days at 4/25°C. The results showed no significant differences among these samples.



SARS-CoV-2 S-trimer Protein (C-6His)(Cat. No.: DRA49) can bind 293-ACE2 Overexpressed Cells (Cat. No.: XCC14). The percentage for positive cell is 92.1%.

- S Protein RBD (C-mFc) (Cat. No.: DRA32)



Purity: Greater than 95%


EC50: 62 ng/ml

EC50: 13 ng/ml



Validation Data

SARS-CoV-2 S Protein



- S Protein RBD-SD1 (C-6His) (Cat. No.: DRA42)



Purity: Greater than 95% as determined by reducing SDS-PAGE and SEC-HPLC.



Batch stability: It is confirmed by binding ability with Anti-SARS-CoV-2-S1 mAb(5D9) or ACE-2. The result showed no significant differences among these samples.



Freeze-thaw stability: Stability is tested by binding ability with Anti-SARS-CoV-2-S1 mAb (5D9) or ACE-2 after 14 times freeze-thaw . The results showed no significant differences among these samples.





Distributed by:

CliniSciences Group

Validation Data



SARS-CoV-2 S Protein

- S Protein RBD-SD1 (C-6His) (Cat. No.: DRA42)



Stability is tested by binding ability with Anti-SARS-CoV-2-S1 mAb (5D9) or ACE-2 after storage for 14 days at 4/25°C. The results showed no significant differences among these samples.

- S1 Protein (C-Fc) (Cat. No.: DRA37)





Purity: Greater than 90% EC50: 0.85 µg/ml

Validation Data



SARS-CoV-2 N Protein

- Nucleocapsid Protein (C-6His) (Cat. No.: DRA91)





Purity: Greater than 95%

Purity: Greater than 91%



EC50: 55.05 ng/ml

Closely related to infectious serum (R²=0.9988)




Stability: SARS-CoV-2 Nucleocapsid protein stored for 5 days at 37°C, the result showed activity changes within 20%, each sample was repeated 10 times by fluorescence immunochromatography Assay.

Stability: SARS-CoV-2 Nucleocapsid protein stored for 7 days at 4°C, the result showed activity changes within 20%, each sample was repeated 10 times by fluorescence immunochromatography Assay.

Validation Data


SARS-CoV-2 N Protein

- Nucleocapsid Protein (C-6His) (Cat. No.: DRA91)



Stability: After four cycles of freezing and thawing, the result showed no significant differences among these SARS-CoV-2 Nucleocapsid protein samples, each sample was repeated 10 times by fluorescence immunochromatography Assay.

Concentration(pg/ml)	NC	1000	500	100	50	25	Concentration(pg/ml)	NC	500	100
Company N	-	+++	++	+	+	-	Company W	-	+	+



Sensitivity: The lowest recombinant N protein concentration for positive result: 50pg/ml




Sensitivity: The lowest recombinant N protein concentration for positive result: 100pg/ml


Validation Data

SARS-CoV-2 Receptor Protein


- Recombinant Human ACE-2 (C-Fc) (Cat. No.: C05Y)




Purity: Greater than 95%




EC50: 25-250 ng/ml




Batch stability is confirmed by binding ability with SARS-CoV-2 S Protein RBD-SD1. The result showed no significant differences among these samples.



Stability is tested by binding ability with SARS-CoV-2 S Protein RBD-SD1 after 14 times freeze-thaw. The results showed no significant differences among these samples.





Stability is tested by binding ability with SARS-CoV-2 S Protein RBD-SD1 after storage for 14 days at 4/25°C. The results showed no significant differences among these samples.




Validation Data

Pseudovirus

- SARS-CoV-2 (D614G) -GFP-Luc Pseudovirus (Cat. No.: XCV03)




Flow cytometry and Fluorescence microscope detection for Pseudovirus infection and antibody neutralisation.



Luciferase values detection for Pseudovirus infection and antibody neutralisation.

- Quantification of SARS-CoV-2 neutralizing antibody by a pseudotyped virus-based assay



Luciferase values detection for SARS-CoV-2 antibody neutralisation against SARS-CoV-2 Variants.

15 Immunodiagnosics Reagent Solutions

Product Name	Cat. No.
IL-6 Quantitative Detection Uncutted Strip (TRFIA)	D001B
IL-6 Quantitative Detection Kit (CLIA-AP)	D001C
IL-6 Quantitative Detection Kit (CLIA-AE)	D001D
African Swine Fever Virus Antibody Test Kit (ELISA)	DN02A
ADP Quantitative Detection Uncutted Strip (TRFIA)	D008B
ADP Quantitative Detection Kit (CLIA-AP)	D008C
ADP Quantitative Detection Kit (CLIA-AE)	D008D
ADV Ag Detection Uncutted Strip (TRFIA)	D024B
AT III Quantitative Detection Uncutted Strips (TRFIA)	D019B
D-Dimer Quantitative Detection Uncutted Strips (TRFIA)	D018B
FDP Quantitative Detection Uncutted Strips (TRFIA)	D020B
FluA Ag Detection Uncutted Strip (LFIA)	D021B
FluB Ag Detection Uncutted Strip (LFIA)	D022B
FluA/FluB Ag Detection Uncutted Strip (LFIA)	D025B
FluA/FluB/ADV Ag Detection Uncutted Strip (LFIA)	D028B
FluA/FluB/ADV/RSV Ag Detection Uncutted Strip (LFIA)	D027B
FluA/FluB/SARS-CoV-2 Ag Detection Uncutted Strip (LFIA)	D026B
FluA/FluB/SARS-CoV-2/ADV Ag Detection Uncutted Strip (LFIA)	D030B
FluA/FluB/SARS-CoV-2/RSV Ag Detection Uncutted Strip (LFIA)	D029B
Gal-3 Quantitative Detection Uncutted Strip (TRFIA)	D017B
Gal-3 Quantitative Detection Kit (CLIA-AP)	D017C
Gal-3 Quantitative Detection Kit (CLIA-AE)	D017D
GDF-15 Quantitative Detection Uncutted Strip (TRFIA)	D007B
GDF-15 Quantitative Detection Kit (CLIA-AP)	D007C
GDF-15 Quantitative Detection Kit (CLIA-AE)	D007D
Lp-PLA2 Quantitative Detection Uncutted Strip (TRFIA)	D006B
MMP-3 Quantitative Detection Uncutted Strip (TRFIA)	D009B
MMP-3 Quantitative Detection Kit (CLIA-AP)	D009C
MMP-3 Quantitative Detection Kit (CLIA-AE)	D009D
MPO Quantitative Detection Uncutted Strip (TRFIA)	D016B
MPO Quantitative Detection Kit (CLIA-AP)	D016C
MPO Quantitative Detection Kit (CLIA-AE)	D016D
MPXV Ag Detection Uncutted Strip (LFIA)	D015B
RSV Ag Detection Uncutted Strip (LFIA)	D023B
sCD40L Quantitative Detection Uncutted Strip (TRFIA)	D014B

Distributed by:

CliniSciences Group

15 Immunodiagnosics Reagent Solutions

Product Name	Cat. No.
sST2 Quantitative Detection Uncutted Strip (TRFIA)	D002B
sST2 Quantitative Detection Kit (CLIA-AP)	D002C
sST2 Quantitative Detection Kit (CLIA-AE)	D002D
SARS-CoV-2 Ab (IgG) Detection Kit (TRFIA) 1.0	D003C
SARS-CoV-2 Ab (IgG) Detection Kit (LFIA) 1.0	D003D
SARS-CoV-2 Ab (IgG) Detection Kit (TRFIA) 2.0	D003E
SARS-CoV-2 Ab (IgG) Detection Kit (LFIA) 2.0	D003F
SARS-CoV-2 Ag Detection Uncutted Strip (LFIA)	D004J

Distributed by:

CliniSciences Group

CliniSciences Group

Austria

Company: CliniSciences GmbH
Address: Sternwartestrasse 76, A-1180
Wien - Austria
Telephone: +43 720 115 580
Fax: +43 720 115 577
Email: oesterreich@clinisciences.com
Web: <https://www.clinisciences.com>



Belgium

Company: CliniSciences S.R.L
Address: Avenue Stalingrad 52, 1000
Brussels - Belgium
Telephone: +32 2 31 50 800
Fax: +32 2 31 50 801
Email: belgium@clinisciences.com
Web: <https://www.clinisciences.com>



Denmark

Company: CliniSciences ApS
Address: Oesterbrogade 226, st. 1,
Copenhagen, 2100 - Denmark
Telephone: +45 89 888 349
Fax: +45 89 884 064
Email: denmark@clinisciences.com
Web: <https://www.clinisciences.com>



Finland

Company: CliniSciences ApS
Address: Oesterbrogade 226, st. 1,
Copenhagen, 2100 - Denmark
Telephone: +45 89 888 349
Fax: +45 89 884 064
Email: suomi@clinisciences.com
Web: <https://www.clinisciences.com>



France

Company: CliniSciences S.A.S
Address: 74 Rue des Suisses, 92000
Nanterre- France
Telephone: +33 9 77 40 09 09
Fax: +33 9 77 40 10 11
Email: info@clinisciences.com
Web: <https://www.clinisciences.com>



Germany

Company: Biotrend Chemikalien GmbH
Address: Wilhelm-Mauser-Str. 41-43,
50827 Köln - Germany
Telephone: +49 221 9498 320
Fax: +49 221 9498 325
Email: info@biotrend.com
Web: <https://www.biotrend.com>



Iceland

Company: CliniSciences ApS
Address: Oesterbrogade 226, st. 1,
Copenhagen, 2100 - Denmark
Telephone: +45 89 888 349
Fax: +45 89 884 064
Email: island@clinisciences.com
Web: <https://www.clinisciences.com>



Ireland

Company: CliniSciences Limited
Address: Ground Floor, 71 lower Baggot street
Dublin D02 P593 - Ireland
Telephone: +353 1 6971 146
Fax: +353 1 6971 147
Email: ireland@clinisciences.com
Web: <https://www.clinisciences.com>



Italy

Company: CliniSciences S.r.l
Address: Via Maremmana inferiore 378
Roma 00012 Guidonia Montecelio - Italy
Telephone: +39 06 94 80 56 71
Fax: +39 06 94 80 00 21
Email: italia@clinisciences.com
Web: <https://www.clinisciences.com>



Netherlands

Company: CliniSciences B.V.
Address: Kraijenhoffstraat 137A,
1018RG Amsterdam, - Netherlands
Telephone: +31 85 2082 351
Fax: +31 85 2082 353
Email: nederland@clinisciences.com
Web: <https://www.clinisciences.com>



Norway

Company: CliniSciences AS
Address: c/o MerVerdi Munkeordtunet 10
1164 Oslo - Norway
Telephone: +47 21 988 882
Email: norge@clinisciences.com
Web: <https://www.clinisciences.com>



Poland

Company: CliniSciences sp.z.o.o.
Address: ul. Rotmistrza Witolda Pileckiego 67
lok. 200 - 02-781 Warszawa -Poland
Telephone: +48 22 307 0535
Fax: +48 22 307 0532
Email: polska@clinisciences.com
Web: <https://www.clinisciences.com>



Portugal

Company: Quimigen Unipessoal LDA
Address: Rua Almada Negreiros, Lote 5, Loja 14,
2615-275 Alverca Do Ribatejo - Portugal
Telephone: +351 30 8808 050
Fax: +351 30 8808 052
Email: info@quimigen.com
Web: <https://www.quimigen.pt>



Spain

Company: CliniSciences Lab Solutions
Address: C/ Hermanos del Moral 13
(Bajo E), 28019, Madrid - Spain
Telephone: +34 916 750 700
Fax: +34 91 269 40 74
Email: espana@clinisciences.com
Web: <https://www.clinisciences.com>



Sweden

Company: CliniSciences ApS
Address: Oesterbrogade 226, st. 1,
Copenhagen, 2100 - Denmark
Telephone: +45 89 888 349
Fax: +45 89 884 064
Email: sverige@clinisciences.com
Web: <https://www.clinisciences.com>



Switzerland

Company: CliniSciences AG
Address: Fracht Ost Flughafen Kloten
CH-8058 Zürich - Switzerland
Telephone: +41 (044) 805 76 81
Fax: +41 (044) 805 76 75
Email: switzerland@clinisciences.com
Web: <https://www.clinisciences.com>



UK

Company: CliniSciences Limited
Address: 11 Progress Business center, Whittle
Parkway, SL1 6DQ Slough- United Kingdom
Telephone: +44 (0)1753 866 511
or +44 (0) 330 684 0982
Fax: +44 (0)1753 208 899
Email: uk@clinisciences.com
IWeb: <https://www.clinisciences.com>



USA

Company: Biotrend Chemicals LLC
Address: c/o Carr Riggs Ingram,
500 Grand Boulevard, Suite 210 Miramar
Beach, FL 32550- USA
Telephone: +1 850 650 7790
Fax: +1 850 650 4383
Email: info@biotrend-usa.com
Web: <https://www.biotrend-usa.com>

